Petreus et al

Developing effective oncology therapies involves defining the right schedules to minimize side effects and maximise efficacy. This requires an accurate understanding of the pharmacokinetic/pharmacodynamics PK/PD relationship of the compound(s). Animal and human PKs can differ significantly and many failures of novel therapies are due to a missing physiologically relevant link between preclinical and clinical data.​

In vitro experiments are mainly performed at fixed concentrations and do not explore (PK/PD) relationships, which represents a limit to their translational relevance. To overcome this issue, we have developed a microphysiological system (MPS) able to explore PK/PD efficiency relationships on 3D tumour models/organoids, following mono or combination therapy.